COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:

Jefferies London Healthcare Conference

Presentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m. GMT

London, UK

The presentation will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

Piper Sandler 37th Annual Healthcare Conference

Fireside Chat Date and Time: Tuesday, December 2, 2025, at 2:30 p.m. ET

New York, NY

The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

Evercore Healthcare Conference

Thursday, December 4, 2025

Coral Gables, FL

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contacts:

Ian Karp

Head of Investor Relations

 

Danielle Jesse

Director, Investor Relations

 

Media Contact:

Cheryl Wheeler

Head of Corporate Communications

 



EN
12/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare ConferencePresentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m. GMTLondon, UK The presentation will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation. Piper Sandler 37th Annual Health...

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 30,000 shares at 40.525USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Gu...

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance – Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3...

 PRESS RELEASE

Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her P...

Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment ​​​– Long-time advocate, Paris Hilton, shares her personal ADHD journey from childhood to adulthood to encourage others to speak to their healthcare provider about appropriate treatment options – STOUGHTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, entrepreneur, musician, ​author, and advocate, ​are collaborating ​​to share her personal experience living ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch